1. Home
  2. HUN vs ADPT Comparison

HUN vs ADPT Comparison

Compare HUN & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Huntsman Corporation

HUN

Huntsman Corporation

HOLD

Current Price

$14.53

Market Cap

2.6B

Sector

Industrials

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$13.80

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HUN
ADPT
Founded
1970
2009
Country
United States
United States
Employees
N/A
624
Industry
Major Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.2B
IPO Year
2004
2019

Fundamental Metrics

Financial Performance
Metric
HUN
ADPT
Price
$14.53
$13.80
Analyst Decision
Hold
Strong Buy
Analyst Count
11
9
Target Price
$12.09
$17.78
AVG Volume (30 Days)
4.9M
1.5M
Earning Date
04-30-2026
05-05-2026
Dividend Yield
2.64%
N/A
EPS Growth
N/A
63.89
EPS
N/A
N/A
Revenue
$5,683,000,000.00
$276,976,000.00
Revenue This Year
$3.08
$3.98
Revenue Next Year
$5.27
$22.72
P/E Ratio
N/A
N/A
Revenue Growth
N/A
54.77
52 Week Low
$7.30
$8.97
52 Week High
$15.90
$20.76

Technical Indicators

Market Signals
Indicator
HUN
ADPT
Relative Strength Index (RSI) 55.53 50.69
Support Level $13.10 $12.22
Resistance Level $15.60 $15.27
Average True Range (ATR) 0.63 0.78
MACD -0.08 0.03
Stochastic Oscillator 59.72 52.13

Price Performance

Historical Comparison
HUN
ADPT

About HUN Huntsman Corporation

Huntsman Corp is a USA-based manufacturer of differentiated organic chemical products. The product portfolio of the company comprises Methyl diphenyl diisocyanate (MDI), Amines, Maleic anhydride, and Epoxy-based polymer formulations. The company's products are used in adhesives, aerospace, automotive, and construction products, and others. Its operating segments are Polyurethanes, Performance Products, and Advanced Materials. The company derives the majority of its revenue from the Polyurethanes segment, which includes MDI, polyols, TPU (thermoplastic polyurethane), and other polyurethane-related products. Its geographical segments are the United States & Canada, Europe, Asia-Pacific, and the Rest of the world.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: